Table 2. Percentages of viable cells... | American Society of Hematology

Table 2.

Percentages of viable cells expressing lineage specific markers and dead cells (reported only for the erythroid lineage at days 7-10) on unilineage cultures at different time points after 20 hours of incubation with the indicated treatments

Days 3-5	CD33⁺ Myeloid	CD61⁺Megakaryocytic	Glycophorin⁺ Erythroid Cultures
Control^*	62 ± 12 (3)^†	38 ± 10.5 (3)^†	8.3 ± 3 (5)^†
TRAIL^‡	58 ± 14	36 ± 11	6.6 ± 3.6
CH11^2-153	62 ± 14	43 ± 7.3	7.4 ± 2.5

Days 3-5	CD33⁺ Myeloid	CD61⁺Megakaryocytic	Glycophorin⁺ Erythroid Cultures
Control^*	62 ± 12 (3)^†	38 ± 10.5 (3)^†	8.3 ± 3 (5)^†
TRAIL^‡	58 ± 14	36 ± 11	6.6 ± 3.6
CH11^2-153	62 ± 14	43 ± 7.3	7.4 ± 2.5

Days 7-10	CD15⁺ Granulocytic	CD14⁺ Monocytic	CD61⁺Megakaryocytic	Glycophorin⁺ Erythroid Cultures
Days 7-10	CD15⁺ Granulocytic	CD14⁺ Monocytic	CD61⁺Megakaryocytic	Viable	Dead Cells
Control^*	35 ± 16 (7)^†	33 ± 15 (4)^†	49 ± 18 (6)^†	42 ± 12 (13)^†	14 ± 6
TRAIL^‡	32 ± 12	35 ± 13	52 ± 16	21 ± 10^2-155	29 ± 4.5
CH11^2-153	35 ± 9	32 ± 18	47 ± 20	22 ± 13^2-155	30 ± 11

Days 7-10	CD15⁺ Granulocytic	CD14⁺ Monocytic	CD61⁺Megakaryocytic	Glycophorin⁺ Erythroid Cultures
Days 7-10	CD15⁺ Granulocytic	CD14⁺ Monocytic	CD61⁺Megakaryocytic	Viable	Dead Cells
Control^*	35 ± 16 (7)^†	33 ± 15 (4)^†	49 ± 18 (6)^†	42 ± 12 (13)^†	14 ± 6
TRAIL^‡	32 ± 12	35 ± 13	52 ± 16	21 ± 10^2-155	29 ± 4.5
CH11^2-153	35 ± 9	32 ± 18	47 ± 20	22 ± 13^2-155	30 ± 11

Days 12-14	CD15⁺ Granulocytic	CD14⁺Monocytic	CD61⁺ Megakaryocytic	Glycophorin⁺ Erythroid Cultures
Control^*	67 ± 14 (8)^†	52 ± 12 (3)^†	89 ± 5 (3)^†	70 ± 14 (6)^†
TRAIL^‡	70 ± 13	55 ± 8	87 ± 7	68 ± 13
CH11^2-153	65 ± 16	52 ± 9	86 ± 8	61.5 ± 12

Days 12-14	CD15⁺ Granulocytic	CD14⁺Monocytic	CD61⁺ Megakaryocytic	Glycophorin⁺ Erythroid Cultures
Control^*	67 ± 14 (8)^†	52 ± 12 (3)^†	89 ± 5 (3)^†	70 ± 14 (6)^†
TRAIL^‡	70 ± 13	55 ± 8	87 ± 7	68 ± 13
CH11^2-153	65 ± 16	52 ± 9	86 ± 8	61.5 ± 12

Data are reported as mean ± SD of 3-13 separate experiments.

His-tag + irrelevant IgM.

†

Number of experiments performed in parenthesis.

‡

TRAIL 1 g/mL. TRAIL indicates tumor necrosis factor (TNF)-related apoptosis-inducing ligand.

F2-153

200 ng/mL of anti-CD95 triggering monoclonal antibody (CH11).

F2-155

Statistically significant difference (P < .05) between control, TRAIL-, and CH11-treated cells.

View Large

This Feature Is Available To Subscribers Only